We are happy to report that we successfully defended Merck’s formulation patent EP 3 996 688 for c-Met inhibitor Tepotinib (TEPMETKO®) in opposition proceedings at the hearing on July 9, 2025. The patent is upheld as granted.
Continue reading
Maiwald acted as legal advisor to Royalty Pharma in connection with an innovative funding agreement totaling up to $2 billion with Revolution Medicines. The transaction includes up to $1.25 billion in synthe...
Continue reading
Cyprumed GmbH and Merck & Co., Inc. have entered a Non-Exclusive License and Option Agreement to develop oral formulations of peptides using Cyprumed’s drug delivery technology. MSD gains global non-exclusive rights...
Continue reading
All press coverage
Royalty Pharma plc and Revolution Medicines, Inc. have announced a strategic funding collaboration of up to $2 billion to support the global development and commercialization of Revolution’s RAS(ON) inhibitor portfolio, particularly the clinical advancement of lead candida...
Continue reading
In a significant development, the European Patent Office (EPO) has revoked Salix Pharmaceuticals’ European patent for the antibiotic rifaximin. In decision T 0162/22, the EPO Board of Appeal confirmed the revocation of European Patent EP 2 252 148 following the wit...
Continue reading
A European Patent Office board of appeal said in a ruling published on March 10th that Roche Diagnostics GmbH proved Verinata Health Inc.'s blueprint lacks an inventive step over an earlier international patent application setting out a similar way of testing "free-floating ...
Continue reading
All press releases